Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions Inc (NYSE: EBS) is a leader in developing medical countermeasures for public health threats, with a focus on biodefense and emergency response solutions. This page provides investors and stakeholders with centralized access to official press releases, regulatory updates, and strategic developments from the life sciences innovator.
Discover timely updates on key initiatives including NARCAN distribution, government contract awards, and advancements in vaccine manufacturing. Our curated news collection covers earnings reports, partnership announcements, and progress on treatments addressing biological threats like anthrax and smallpox.
Stay informed about Emergent's role in global health security through updates on FDA submissions, manufacturing facility expansions, and collaborations with agencies like BARDA. Content is organized chronologically for easy tracking of operational milestones and financial performance.
Bookmark this page for direct access to verified corporate communications and analysis of how EBS navigates complex regulatory environments while maintaining its position as a critical partner in national preparedness programs.
Emergent BioSolutions Inc. (NYSE: EBS) reported Q2 2021 financial results, reaffirming its 2021 revenue forecast of $1.7 - $1.9 billion. Total revenues for Q2 were $397.5 million, a slight increase of 1% YoY, while net income plummeted 95% to $4.6 million. The company resumed production of Johnson & Johnson’s COVID-19 vaccine after FDA approval and secured contracts with U.S. and Canadian governments valued at over $238 million. Adjusted EBITDA declined 68% to $49.5 million, reflecting higher costs and inventory write-offs. The company anticipates Q3 revenues between $400 million and $500 million.
Emergent BioSolutions (NYSE:EBS) announced the resumption of production at its Bayview facility for Johnson & Johnson's Covid-19 vaccine bulk drug substance, following FDA reviews and a quality enhancement plan. CEO Robert Kramer highlighted this as a critical milestone in addressing public health threats. The company committed extensive resources to meet FDA standards and aims to ensure a strong supply chain for the vaccine. Emergent positions itself as a vital partner in epidemic preparedness and expresses gratitude towards government and industry collaborators.
Emergent BioSolutions partners with national nonprofit organizations to launch the Reverse the Silence campaign, raising awareness about opioid overdoses. The initiative features stories from Darren Waller and Dani Schaffer, who share personal experiences with addiction. According to CDC data, over 93,000 Americans died from drug overdoses in 2020, with opioids involved in 80% of those deaths. The campaign aims to encourage open communication about opioid risks and promote emergency preparedness.
Emergent BioSolutions Inc. (NYSE: EBS) will hold a conference call on July 29, 2021, at 5:00 PM ET to discuss its Q2 2021 financial results and provide revenue guidance for Q3 2021 and the full year. Investors can join via phone or webcast, with access details provided. Emergent aims to enhance life through its specialty products and services dedicated to public health, aspiring to protect or enhance one billion lives by 2030. For more details, visit their official website.
Emergent BioSolutions (NYSE:EBS) announced that two batches of its COVID-19 vaccine have received FDA authorization for emergency use, produced at the Bayview facility. The company is actively working with the FDA to address previous observations and aims to resume production soon. Emergent's Bayview facility, designated as a Center for Innovation in Advanced Development and Manufacturing, has been crucial for COVID-19 vaccine readiness since mid-2020. However, the company acknowledges the challenges of timely and sufficient vaccine production.
Emergent BioSolutions reported promising two-year data from its Phase 2 clinical trial for the chikungunya virus VLP vaccine, demonstrating a significant immune response. The study involved 415 healthy adults, showing that the SNA mean titers were 19 times higher than pre-vaccination levels after a single 40 µg dose. The vaccine was well-tolerated, with mostly mild side effects. All participants remained seropositive at one and two years post-vaccination. This data supports moving to a Phase 3 trial aimed at addressing the unmet need for chikungunya vaccination.
Emergent BioSolutions (NYSE: EBS) will host its 2021 Annual Meeting of Stockholders as a virtual-only event on May 20, 2021, at 9:00 AM EDT. Eligible stockholders can participate by accessing the meeting online at www.virtualshareholdermeeting.com/EBS2021 using their unique Control Number. Guests can attend in listen-only mode without voting rights. The company encourages participants to log in 15 minutes early. A replay of the event will be available on Emergent's website.
Emergent BioSolutions (NYSE: EBS) announced participation in upcoming investor conferences. The company will hold 1-on-1 meetings at the Goldman Sachs Credit and Leveraged Finance Conference on May 17, 2021, and at the Benchmark Company Healthcare House Call Conference on May 26, 2021. Additionally, a company presentation is scheduled during the Singular Research Spring Select Webcall on May 27, 2021, at 8:00 am Pacific / 11:00 am Eastern. Webcast presentations will discuss recent business developments and financial results, accessible live and via replay on the Emergent website.
Emergent BioSolutions (EBS) reported Q1 2021 financial results with total revenues of $343.0 million, an 78% increase from Q1 2020. The net income was $69.7 million, compared to a loss of $12.5 million in Q1 2020. Adjusted EBITDA rose to $123.5 million, up from $15.3 million. Product sales decreased by 7% to $137.9 million, primarily due to lower sales of certain products. Revenue from contract development and manufacturing services surged to $183.8 million, attributed to partnerships addressing COVID-19. The company revised its 2021 revenue forecast to $1.7 - $1.9 billion.
The FDA has completed its inspection of Emergent BioSolutions' Baltimore-Bayview facility, providing specific feedback to enhance operations. Emergent is committed to collaborating with the FDA and Johnson & Johnson to address identified issues promptly. While acknowledging the shortcomings, the company expresses confidence in rectifying them quickly, emphasizing its workforce's dedication to producing high-quality COVID-19 vaccines. The press release highlights the importance of maintaining strong relationships with manufacturing partners and outlines the specific steps necessary for operational improvements.
FAQ
What is the current stock price of Emergent Biosolutions (EBS)?
What is the market cap of Emergent Biosolutions (EBS)?
